Effect of central dialysis fluid delivery system on markers of inflammation in hemodialysis patients
Background The utilization of ultrapure dialysate has been shown to decrease dialysate contamination and mitigate inflammatory responses. The central dialysate delivery system (CDDS) has the potential to attain a level of purity similar to ultrapure dialysate. Nevertheless, there is limited research...
Ausführliche Beschreibung
Autor*in: |
Ni, Yanhong [verfasserIn] Wu, Wenhui [verfasserIn] Zhou, Hua [verfasserIn] Li, Min [verfasserIn] Zhu, Xiying [verfasserIn] Niu, Hongyan [verfasserIn] Liu, Jinfeng [verfasserIn] Xue, Lina [verfasserIn] Liu, Yeqian [verfasserIn] Yang, Min [verfasserIn] |
---|
Format: |
E-Artikel |
---|---|
Sprache: |
Englisch |
Erschienen: |
2024 |
---|
Schlagwörter: |
---|
Anmerkung: |
© The Author(s) 2024 |
---|
Übergeordnetes Werk: |
Enthalten in: BMC nephrology - BioMed Central, 2000, 25(2024), 1 vom: 19. Sept. |
---|---|
Übergeordnetes Werk: |
volume:25 ; year:2024 ; number:1 ; day:19 ; month:09 |
Links: |
---|
DOI / URN: |
10.1186/s12882-024-03751-3 |
---|
Katalog-ID: |
SPR057390053 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | SPR057390053 | ||
003 | DE-627 | ||
005 | 20240920064740.0 | ||
007 | cr uuu---uuuuu | ||
008 | 240920s2024 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1186/s12882-024-03751-3 |2 doi | |
035 | |a (DE-627)SPR057390053 | ||
035 | |a (SPR)s12882-024-03751-3-e | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
082 | 0 | 4 | |a 610 |q VZ |
084 | |a 44.00 |2 bkl | ||
100 | 1 | |a Ni, Yanhong |e verfasserin |4 aut | |
245 | 1 | 0 | |a Effect of central dialysis fluid delivery system on markers of inflammation in hemodialysis patients |
264 | 1 | |c 2024 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
500 | |a © The Author(s) 2024 | ||
520 | |a Background The utilization of ultrapure dialysate has been shown to decrease dialysate contamination and mitigate inflammatory responses. The central dialysate delivery system (CDDS) has the potential to attain a level of purity similar to ultrapure dialysate. Nevertheless, there is limited research examining the impact of CDDS on inflammation in comparison to single-patient dialysis fluid delivery system(SPDDS). This study aims to investigate the effects of CDDS utilizing ultrapure dialysate on ameliorating the microinflammatory state in hemodialysis patients. Method A retrospective cohort clinical study enrolled a total of 125 hemodialysis patients, with 58 patients from the CDDS unit and 67 patients from the SPDDS unit. Each participant was monitored for a period of 6 months, and the repeated measurement data was analyzed using a generalized linear mixed models (GLMM). Results The average age of the studty cohort was 56.22 ± 12.64 years. The GLMM analysis showed a significant time*group interaction effect on hs-CRP changes over the follow-up period (β = -1.966, $ F_{Time* CDDS group} $ = 13.389, P < 0.001). A linear mixed model analysis with random slope showed that a different slope was observed between CDDS group and SPDDS group ($ β_{CDDS} $ =—0.793; $ β_{SPDDS} $ = 0.791), indicating a decreased hs-CRP levels in CDDS group, while increased in the SPDDS group over the follow-up period. However, no significant time*group interaction effect were observed on albumin and $ β_{2} $-microglobulin levels during follow-up period($ β_{2} $-microglobulin: β = -0.658, $ F_{Time* CDDS group} $ = 1.228, P = 0.269; albumin: β = 0.012, $ F_{Time* CDDS group} $ = 1.429, P = 0.233). Conclusion Using ultrapure dialysate in the CDDS is associated with an improvement in hs-CRP levels compared to standard dialysate, which might confer long-term clinical advantages. | ||
650 | 4 | |a Maintenance hemodialysis |7 (dpeaa)DE-He213 | |
650 | 4 | |a Ultrapure dialysate |7 (dpeaa)DE-He213 | |
650 | 4 | |a Central Dialysate Delivery system |7 (dpeaa)DE-He213 | |
650 | 4 | |a CDDS |7 (dpeaa)DE-He213 | |
650 | 4 | |a Inflammation |7 (dpeaa)DE-He213 | |
700 | 1 | |a Wu, Wenhui |e verfasserin |4 aut | |
700 | 1 | |a Zhou, Hua |e verfasserin |4 aut | |
700 | 1 | |a Li, Min |e verfasserin |4 aut | |
700 | 1 | |a Zhu, Xiying |e verfasserin |4 aut | |
700 | 1 | |a Niu, Hongyan |e verfasserin |4 aut | |
700 | 1 | |a Liu, Jinfeng |e verfasserin |4 aut | |
700 | 1 | |a Xue, Lina |e verfasserin |4 aut | |
700 | 1 | |a Liu, Yeqian |e verfasserin |4 aut | |
700 | 1 | |a Yang, Min |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t BMC nephrology |d BioMed Central, 2000 |g 25(2024), 1 vom: 19. Sept. |w (DE-627)326643672 |w (DE-600)2041348-8 |x 1471-2369 |7 nnns |
773 | 1 | 8 | |g volume:25 |g year:2024 |g number:1 |g day:19 |g month:09 |
856 | 4 | 0 | |u https://dx.doi.org/10.1186/s12882-024-03751-3 |m X:SPRINGER |x Resolving-System |z kostenfrei |3 Volltext |
912 | |a SYSFLAG_0 | ||
912 | |a GBV_SPRINGER | ||
912 | |a SSG-OLC-PHA | ||
912 | |a GBV_ILN_11 | ||
912 | |a GBV_ILN_20 | ||
912 | |a GBV_ILN_22 | ||
912 | |a GBV_ILN_23 | ||
912 | |a GBV_ILN_24 | ||
912 | |a GBV_ILN_39 | ||
912 | |a GBV_ILN_40 | ||
912 | |a GBV_ILN_60 | ||
912 | |a GBV_ILN_62 | ||
912 | |a GBV_ILN_63 | ||
912 | |a GBV_ILN_65 | ||
912 | |a GBV_ILN_69 | ||
912 | |a GBV_ILN_73 | ||
912 | |a GBV_ILN_74 | ||
912 | |a GBV_ILN_95 | ||
912 | |a GBV_ILN_105 | ||
912 | |a GBV_ILN_110 | ||
912 | |a GBV_ILN_151 | ||
912 | |a GBV_ILN_161 | ||
912 | |a GBV_ILN_170 | ||
912 | |a GBV_ILN_206 | ||
912 | |a GBV_ILN_213 | ||
912 | |a GBV_ILN_230 | ||
912 | |a GBV_ILN_285 | ||
912 | |a GBV_ILN_293 | ||
912 | |a GBV_ILN_602 | ||
912 | |a GBV_ILN_2003 | ||
912 | |a GBV_ILN_2014 | ||
912 | |a GBV_ILN_4012 | ||
912 | |a GBV_ILN_4037 | ||
912 | |a GBV_ILN_4112 | ||
912 | |a GBV_ILN_4125 | ||
912 | |a GBV_ILN_4126 | ||
912 | |a GBV_ILN_4249 | ||
912 | |a GBV_ILN_4305 | ||
912 | |a GBV_ILN_4306 | ||
912 | |a GBV_ILN_4307 | ||
912 | |a GBV_ILN_4313 | ||
912 | |a GBV_ILN_4322 | ||
912 | |a GBV_ILN_4323 | ||
912 | |a GBV_ILN_4324 | ||
912 | |a GBV_ILN_4325 | ||
912 | |a GBV_ILN_4338 | ||
912 | |a GBV_ILN_4367 | ||
912 | |a GBV_ILN_4700 | ||
936 | b | k | |a 44.00 |q VZ |
951 | |a AR | ||
952 | |d 25 |j 2024 |e 1 |b 19 |c 09 |
author_variant |
y n yn w w ww h z hz m l ml x z xz h n hn j l jl l x lx y l yl m y my |
---|---|
matchkey_str |
article:14712369:2024----::fetfetadayifudeieyytmnakroifamt |
hierarchy_sort_str |
2024 |
bklnumber |
44.00 |
publishDate |
2024 |
allfields |
10.1186/s12882-024-03751-3 doi (DE-627)SPR057390053 (SPR)s12882-024-03751-3-e DE-627 ger DE-627 rakwb eng 610 VZ 44.00 bkl Ni, Yanhong verfasserin aut Effect of central dialysis fluid delivery system on markers of inflammation in hemodialysis patients 2024 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © The Author(s) 2024 Background The utilization of ultrapure dialysate has been shown to decrease dialysate contamination and mitigate inflammatory responses. The central dialysate delivery system (CDDS) has the potential to attain a level of purity similar to ultrapure dialysate. Nevertheless, there is limited research examining the impact of CDDS on inflammation in comparison to single-patient dialysis fluid delivery system(SPDDS). This study aims to investigate the effects of CDDS utilizing ultrapure dialysate on ameliorating the microinflammatory state in hemodialysis patients. Method A retrospective cohort clinical study enrolled a total of 125 hemodialysis patients, with 58 patients from the CDDS unit and 67 patients from the SPDDS unit. Each participant was monitored for a period of 6 months, and the repeated measurement data was analyzed using a generalized linear mixed models (GLMM). Results The average age of the studty cohort was 56.22 ± 12.64 years. The GLMM analysis showed a significant time*group interaction effect on hs-CRP changes over the follow-up period (β = -1.966, $ F_{Time* CDDS group} $ = 13.389, P < 0.001). A linear mixed model analysis with random slope showed that a different slope was observed between CDDS group and SPDDS group ($ β_{CDDS} $ =—0.793; $ β_{SPDDS} $ = 0.791), indicating a decreased hs-CRP levels in CDDS group, while increased in the SPDDS group over the follow-up period. However, no significant time*group interaction effect were observed on albumin and $ β_{2} $-microglobulin levels during follow-up period($ β_{2} $-microglobulin: β = -0.658, $ F_{Time* CDDS group} $ = 1.228, P = 0.269; albumin: β = 0.012, $ F_{Time* CDDS group} $ = 1.429, P = 0.233). Conclusion Using ultrapure dialysate in the CDDS is associated with an improvement in hs-CRP levels compared to standard dialysate, which might confer long-term clinical advantages. Maintenance hemodialysis (dpeaa)DE-He213 Ultrapure dialysate (dpeaa)DE-He213 Central Dialysate Delivery system (dpeaa)DE-He213 CDDS (dpeaa)DE-He213 Inflammation (dpeaa)DE-He213 Wu, Wenhui verfasserin aut Zhou, Hua verfasserin aut Li, Min verfasserin aut Zhu, Xiying verfasserin aut Niu, Hongyan verfasserin aut Liu, Jinfeng verfasserin aut Xue, Lina verfasserin aut Liu, Yeqian verfasserin aut Yang, Min verfasserin aut Enthalten in BMC nephrology BioMed Central, 2000 25(2024), 1 vom: 19. Sept. (DE-627)326643672 (DE-600)2041348-8 1471-2369 nnns volume:25 year:2024 number:1 day:19 month:09 https://dx.doi.org/10.1186/s12882-024-03751-3 X:SPRINGER Resolving-System kostenfrei Volltext SYSFLAG_0 GBV_SPRINGER SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 44.00 VZ AR 25 2024 1 19 09 |
spelling |
10.1186/s12882-024-03751-3 doi (DE-627)SPR057390053 (SPR)s12882-024-03751-3-e DE-627 ger DE-627 rakwb eng 610 VZ 44.00 bkl Ni, Yanhong verfasserin aut Effect of central dialysis fluid delivery system on markers of inflammation in hemodialysis patients 2024 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © The Author(s) 2024 Background The utilization of ultrapure dialysate has been shown to decrease dialysate contamination and mitigate inflammatory responses. The central dialysate delivery system (CDDS) has the potential to attain a level of purity similar to ultrapure dialysate. Nevertheless, there is limited research examining the impact of CDDS on inflammation in comparison to single-patient dialysis fluid delivery system(SPDDS). This study aims to investigate the effects of CDDS utilizing ultrapure dialysate on ameliorating the microinflammatory state in hemodialysis patients. Method A retrospective cohort clinical study enrolled a total of 125 hemodialysis patients, with 58 patients from the CDDS unit and 67 patients from the SPDDS unit. Each participant was monitored for a period of 6 months, and the repeated measurement data was analyzed using a generalized linear mixed models (GLMM). Results The average age of the studty cohort was 56.22 ± 12.64 years. The GLMM analysis showed a significant time*group interaction effect on hs-CRP changes over the follow-up period (β = -1.966, $ F_{Time* CDDS group} $ = 13.389, P < 0.001). A linear mixed model analysis with random slope showed that a different slope was observed between CDDS group and SPDDS group ($ β_{CDDS} $ =—0.793; $ β_{SPDDS} $ = 0.791), indicating a decreased hs-CRP levels in CDDS group, while increased in the SPDDS group over the follow-up period. However, no significant time*group interaction effect were observed on albumin and $ β_{2} $-microglobulin levels during follow-up period($ β_{2} $-microglobulin: β = -0.658, $ F_{Time* CDDS group} $ = 1.228, P = 0.269; albumin: β = 0.012, $ F_{Time* CDDS group} $ = 1.429, P = 0.233). Conclusion Using ultrapure dialysate in the CDDS is associated with an improvement in hs-CRP levels compared to standard dialysate, which might confer long-term clinical advantages. Maintenance hemodialysis (dpeaa)DE-He213 Ultrapure dialysate (dpeaa)DE-He213 Central Dialysate Delivery system (dpeaa)DE-He213 CDDS (dpeaa)DE-He213 Inflammation (dpeaa)DE-He213 Wu, Wenhui verfasserin aut Zhou, Hua verfasserin aut Li, Min verfasserin aut Zhu, Xiying verfasserin aut Niu, Hongyan verfasserin aut Liu, Jinfeng verfasserin aut Xue, Lina verfasserin aut Liu, Yeqian verfasserin aut Yang, Min verfasserin aut Enthalten in BMC nephrology BioMed Central, 2000 25(2024), 1 vom: 19. Sept. (DE-627)326643672 (DE-600)2041348-8 1471-2369 nnns volume:25 year:2024 number:1 day:19 month:09 https://dx.doi.org/10.1186/s12882-024-03751-3 X:SPRINGER Resolving-System kostenfrei Volltext SYSFLAG_0 GBV_SPRINGER SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 44.00 VZ AR 25 2024 1 19 09 |
allfields_unstemmed |
10.1186/s12882-024-03751-3 doi (DE-627)SPR057390053 (SPR)s12882-024-03751-3-e DE-627 ger DE-627 rakwb eng 610 VZ 44.00 bkl Ni, Yanhong verfasserin aut Effect of central dialysis fluid delivery system on markers of inflammation in hemodialysis patients 2024 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © The Author(s) 2024 Background The utilization of ultrapure dialysate has been shown to decrease dialysate contamination and mitigate inflammatory responses. The central dialysate delivery system (CDDS) has the potential to attain a level of purity similar to ultrapure dialysate. Nevertheless, there is limited research examining the impact of CDDS on inflammation in comparison to single-patient dialysis fluid delivery system(SPDDS). This study aims to investigate the effects of CDDS utilizing ultrapure dialysate on ameliorating the microinflammatory state in hemodialysis patients. Method A retrospective cohort clinical study enrolled a total of 125 hemodialysis patients, with 58 patients from the CDDS unit and 67 patients from the SPDDS unit. Each participant was monitored for a period of 6 months, and the repeated measurement data was analyzed using a generalized linear mixed models (GLMM). Results The average age of the studty cohort was 56.22 ± 12.64 years. The GLMM analysis showed a significant time*group interaction effect on hs-CRP changes over the follow-up period (β = -1.966, $ F_{Time* CDDS group} $ = 13.389, P < 0.001). A linear mixed model analysis with random slope showed that a different slope was observed between CDDS group and SPDDS group ($ β_{CDDS} $ =—0.793; $ β_{SPDDS} $ = 0.791), indicating a decreased hs-CRP levels in CDDS group, while increased in the SPDDS group over the follow-up period. However, no significant time*group interaction effect were observed on albumin and $ β_{2} $-microglobulin levels during follow-up period($ β_{2} $-microglobulin: β = -0.658, $ F_{Time* CDDS group} $ = 1.228, P = 0.269; albumin: β = 0.012, $ F_{Time* CDDS group} $ = 1.429, P = 0.233). Conclusion Using ultrapure dialysate in the CDDS is associated with an improvement in hs-CRP levels compared to standard dialysate, which might confer long-term clinical advantages. Maintenance hemodialysis (dpeaa)DE-He213 Ultrapure dialysate (dpeaa)DE-He213 Central Dialysate Delivery system (dpeaa)DE-He213 CDDS (dpeaa)DE-He213 Inflammation (dpeaa)DE-He213 Wu, Wenhui verfasserin aut Zhou, Hua verfasserin aut Li, Min verfasserin aut Zhu, Xiying verfasserin aut Niu, Hongyan verfasserin aut Liu, Jinfeng verfasserin aut Xue, Lina verfasserin aut Liu, Yeqian verfasserin aut Yang, Min verfasserin aut Enthalten in BMC nephrology BioMed Central, 2000 25(2024), 1 vom: 19. Sept. (DE-627)326643672 (DE-600)2041348-8 1471-2369 nnns volume:25 year:2024 number:1 day:19 month:09 https://dx.doi.org/10.1186/s12882-024-03751-3 X:SPRINGER Resolving-System kostenfrei Volltext SYSFLAG_0 GBV_SPRINGER SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 44.00 VZ AR 25 2024 1 19 09 |
allfieldsGer |
10.1186/s12882-024-03751-3 doi (DE-627)SPR057390053 (SPR)s12882-024-03751-3-e DE-627 ger DE-627 rakwb eng 610 VZ 44.00 bkl Ni, Yanhong verfasserin aut Effect of central dialysis fluid delivery system on markers of inflammation in hemodialysis patients 2024 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © The Author(s) 2024 Background The utilization of ultrapure dialysate has been shown to decrease dialysate contamination and mitigate inflammatory responses. The central dialysate delivery system (CDDS) has the potential to attain a level of purity similar to ultrapure dialysate. Nevertheless, there is limited research examining the impact of CDDS on inflammation in comparison to single-patient dialysis fluid delivery system(SPDDS). This study aims to investigate the effects of CDDS utilizing ultrapure dialysate on ameliorating the microinflammatory state in hemodialysis patients. Method A retrospective cohort clinical study enrolled a total of 125 hemodialysis patients, with 58 patients from the CDDS unit and 67 patients from the SPDDS unit. Each participant was monitored for a period of 6 months, and the repeated measurement data was analyzed using a generalized linear mixed models (GLMM). Results The average age of the studty cohort was 56.22 ± 12.64 years. The GLMM analysis showed a significant time*group interaction effect on hs-CRP changes over the follow-up period (β = -1.966, $ F_{Time* CDDS group} $ = 13.389, P < 0.001). A linear mixed model analysis with random slope showed that a different slope was observed between CDDS group and SPDDS group ($ β_{CDDS} $ =—0.793; $ β_{SPDDS} $ = 0.791), indicating a decreased hs-CRP levels in CDDS group, while increased in the SPDDS group over the follow-up period. However, no significant time*group interaction effect were observed on albumin and $ β_{2} $-microglobulin levels during follow-up period($ β_{2} $-microglobulin: β = -0.658, $ F_{Time* CDDS group} $ = 1.228, P = 0.269; albumin: β = 0.012, $ F_{Time* CDDS group} $ = 1.429, P = 0.233). Conclusion Using ultrapure dialysate in the CDDS is associated with an improvement in hs-CRP levels compared to standard dialysate, which might confer long-term clinical advantages. Maintenance hemodialysis (dpeaa)DE-He213 Ultrapure dialysate (dpeaa)DE-He213 Central Dialysate Delivery system (dpeaa)DE-He213 CDDS (dpeaa)DE-He213 Inflammation (dpeaa)DE-He213 Wu, Wenhui verfasserin aut Zhou, Hua verfasserin aut Li, Min verfasserin aut Zhu, Xiying verfasserin aut Niu, Hongyan verfasserin aut Liu, Jinfeng verfasserin aut Xue, Lina verfasserin aut Liu, Yeqian verfasserin aut Yang, Min verfasserin aut Enthalten in BMC nephrology BioMed Central, 2000 25(2024), 1 vom: 19. Sept. (DE-627)326643672 (DE-600)2041348-8 1471-2369 nnns volume:25 year:2024 number:1 day:19 month:09 https://dx.doi.org/10.1186/s12882-024-03751-3 X:SPRINGER Resolving-System kostenfrei Volltext SYSFLAG_0 GBV_SPRINGER SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 44.00 VZ AR 25 2024 1 19 09 |
allfieldsSound |
10.1186/s12882-024-03751-3 doi (DE-627)SPR057390053 (SPR)s12882-024-03751-3-e DE-627 ger DE-627 rakwb eng 610 VZ 44.00 bkl Ni, Yanhong verfasserin aut Effect of central dialysis fluid delivery system on markers of inflammation in hemodialysis patients 2024 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © The Author(s) 2024 Background The utilization of ultrapure dialysate has been shown to decrease dialysate contamination and mitigate inflammatory responses. The central dialysate delivery system (CDDS) has the potential to attain a level of purity similar to ultrapure dialysate. Nevertheless, there is limited research examining the impact of CDDS on inflammation in comparison to single-patient dialysis fluid delivery system(SPDDS). This study aims to investigate the effects of CDDS utilizing ultrapure dialysate on ameliorating the microinflammatory state in hemodialysis patients. Method A retrospective cohort clinical study enrolled a total of 125 hemodialysis patients, with 58 patients from the CDDS unit and 67 patients from the SPDDS unit. Each participant was monitored for a period of 6 months, and the repeated measurement data was analyzed using a generalized linear mixed models (GLMM). Results The average age of the studty cohort was 56.22 ± 12.64 years. The GLMM analysis showed a significant time*group interaction effect on hs-CRP changes over the follow-up period (β = -1.966, $ F_{Time* CDDS group} $ = 13.389, P < 0.001). A linear mixed model analysis with random slope showed that a different slope was observed between CDDS group and SPDDS group ($ β_{CDDS} $ =—0.793; $ β_{SPDDS} $ = 0.791), indicating a decreased hs-CRP levels in CDDS group, while increased in the SPDDS group over the follow-up period. However, no significant time*group interaction effect were observed on albumin and $ β_{2} $-microglobulin levels during follow-up period($ β_{2} $-microglobulin: β = -0.658, $ F_{Time* CDDS group} $ = 1.228, P = 0.269; albumin: β = 0.012, $ F_{Time* CDDS group} $ = 1.429, P = 0.233). Conclusion Using ultrapure dialysate in the CDDS is associated with an improvement in hs-CRP levels compared to standard dialysate, which might confer long-term clinical advantages. Maintenance hemodialysis (dpeaa)DE-He213 Ultrapure dialysate (dpeaa)DE-He213 Central Dialysate Delivery system (dpeaa)DE-He213 CDDS (dpeaa)DE-He213 Inflammation (dpeaa)DE-He213 Wu, Wenhui verfasserin aut Zhou, Hua verfasserin aut Li, Min verfasserin aut Zhu, Xiying verfasserin aut Niu, Hongyan verfasserin aut Liu, Jinfeng verfasserin aut Xue, Lina verfasserin aut Liu, Yeqian verfasserin aut Yang, Min verfasserin aut Enthalten in BMC nephrology BioMed Central, 2000 25(2024), 1 vom: 19. Sept. (DE-627)326643672 (DE-600)2041348-8 1471-2369 nnns volume:25 year:2024 number:1 day:19 month:09 https://dx.doi.org/10.1186/s12882-024-03751-3 X:SPRINGER Resolving-System kostenfrei Volltext SYSFLAG_0 GBV_SPRINGER SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 44.00 VZ AR 25 2024 1 19 09 |
language |
English |
source |
Enthalten in BMC nephrology 25(2024), 1 vom: 19. Sept. volume:25 year:2024 number:1 day:19 month:09 |
sourceStr |
Enthalten in BMC nephrology 25(2024), 1 vom: 19. Sept. volume:25 year:2024 number:1 day:19 month:09 |
format_phy_str_mv |
Article |
institution |
findex.gbv.de |
topic_facet |
Maintenance hemodialysis Ultrapure dialysate Central Dialysate Delivery system CDDS Inflammation |
dewey-raw |
610 |
isfreeaccess_bool |
true |
container_title |
BMC nephrology |
authorswithroles_txt_mv |
Ni, Yanhong @@aut@@ Wu, Wenhui @@aut@@ Zhou, Hua @@aut@@ Li, Min @@aut@@ Zhu, Xiying @@aut@@ Niu, Hongyan @@aut@@ Liu, Jinfeng @@aut@@ Xue, Lina @@aut@@ Liu, Yeqian @@aut@@ Yang, Min @@aut@@ |
publishDateDaySort_date |
2024-09-19T00:00:00Z |
hierarchy_top_id |
326643672 |
dewey-sort |
3610 |
id |
SPR057390053 |
language_de |
englisch |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000naa a22002652 4500</leader><controlfield tag="001">SPR057390053</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20240920064740.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">240920s2024 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1186/s12882-024-03751-3</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR057390053</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s12882-024-03751-3-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.00</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Ni, Yanhong</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Effect of central dialysis fluid delivery system on markers of inflammation in hemodialysis patients</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2024</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">© The Author(s) 2024</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Background The utilization of ultrapure dialysate has been shown to decrease dialysate contamination and mitigate inflammatory responses. The central dialysate delivery system (CDDS) has the potential to attain a level of purity similar to ultrapure dialysate. Nevertheless, there is limited research examining the impact of CDDS on inflammation in comparison to single-patient dialysis fluid delivery system(SPDDS). This study aims to investigate the effects of CDDS utilizing ultrapure dialysate on ameliorating the microinflammatory state in hemodialysis patients. Method A retrospective cohort clinical study enrolled a total of 125 hemodialysis patients, with 58 patients from the CDDS unit and 67 patients from the SPDDS unit. Each participant was monitored for a period of 6 months, and the repeated measurement data was analyzed using a generalized linear mixed models (GLMM). Results The average age of the studty cohort was 56.22 ± 12.64 years. The GLMM analysis showed a significant time*group interaction effect on hs-CRP changes over the follow-up period (β = -1.966, $ F_{Time* CDDS group} $ = 13.389, P < 0.001). A linear mixed model analysis with random slope showed that a different slope was observed between CDDS group and SPDDS group ($ β_{CDDS} $ =—0.793; $ β_{SPDDS} $ = 0.791), indicating a decreased hs-CRP levels in CDDS group, while increased in the SPDDS group over the follow-up period. However, no significant time*group interaction effect were observed on albumin and $ β_{2} $-microglobulin levels during follow-up period($ β_{2} $-microglobulin: β = -0.658, $ F_{Time* CDDS group} $ = 1.228, P = 0.269; albumin: β = 0.012, $ F_{Time* CDDS group} $ = 1.429, P = 0.233). Conclusion Using ultrapure dialysate in the CDDS is associated with an improvement in hs-CRP levels compared to standard dialysate, which might confer long-term clinical advantages.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Maintenance hemodialysis</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Ultrapure dialysate</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Central Dialysate Delivery system</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">CDDS</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Inflammation</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Wu, Wenhui</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Zhou, Hua</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Li, Min</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Zhu, Xiying</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Niu, Hongyan</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Liu, Jinfeng</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Xue, Lina</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Liu, Yeqian</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Yang, Min</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">BMC nephrology</subfield><subfield code="d">BioMed Central, 2000</subfield><subfield code="g">25(2024), 1 vom: 19. Sept.</subfield><subfield code="w">(DE-627)326643672</subfield><subfield code="w">(DE-600)2041348-8</subfield><subfield code="x">1471-2369</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:25</subfield><subfield code="g">year:2024</subfield><subfield code="g">number:1</subfield><subfield code="g">day:19</subfield><subfield code="g">month:09</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1186/s12882-024-03751-3</subfield><subfield code="m">X:SPRINGER</subfield><subfield code="x">Resolving-System</subfield><subfield code="z">kostenfrei</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_0</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.00</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">25</subfield><subfield code="j">2024</subfield><subfield code="e">1</subfield><subfield code="b">19</subfield><subfield code="c">09</subfield></datafield></record></collection>
|
author |
Ni, Yanhong |
spellingShingle |
Ni, Yanhong ddc 610 bkl 44.00 misc Maintenance hemodialysis misc Ultrapure dialysate misc Central Dialysate Delivery system misc CDDS misc Inflammation Effect of central dialysis fluid delivery system on markers of inflammation in hemodialysis patients |
authorStr |
Ni, Yanhong |
ppnlink_with_tag_str_mv |
@@773@@(DE-627)326643672 |
format |
electronic Article |
dewey-ones |
610 - Medicine & health |
delete_txt_mv |
keep |
author_role |
aut aut aut aut aut aut aut aut aut aut |
collection |
springer |
remote_str |
true |
illustrated |
Not Illustrated |
issn |
1471-2369 |
topic_title |
610 VZ 44.00 bkl Effect of central dialysis fluid delivery system on markers of inflammation in hemodialysis patients Maintenance hemodialysis (dpeaa)DE-He213 Ultrapure dialysate (dpeaa)DE-He213 Central Dialysate Delivery system (dpeaa)DE-He213 CDDS (dpeaa)DE-He213 Inflammation (dpeaa)DE-He213 |
topic |
ddc 610 bkl 44.00 misc Maintenance hemodialysis misc Ultrapure dialysate misc Central Dialysate Delivery system misc CDDS misc Inflammation |
topic_unstemmed |
ddc 610 bkl 44.00 misc Maintenance hemodialysis misc Ultrapure dialysate misc Central Dialysate Delivery system misc CDDS misc Inflammation |
topic_browse |
ddc 610 bkl 44.00 misc Maintenance hemodialysis misc Ultrapure dialysate misc Central Dialysate Delivery system misc CDDS misc Inflammation |
format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
format_main_str_mv |
Text Zeitschrift/Artikel |
carriertype_str_mv |
cr |
hierarchy_parent_title |
BMC nephrology |
hierarchy_parent_id |
326643672 |
dewey-tens |
610 - Medicine & health |
hierarchy_top_title |
BMC nephrology |
isfreeaccess_txt |
true |
familylinks_str_mv |
(DE-627)326643672 (DE-600)2041348-8 |
title |
Effect of central dialysis fluid delivery system on markers of inflammation in hemodialysis patients |
ctrlnum |
(DE-627)SPR057390053 (SPR)s12882-024-03751-3-e |
title_full |
Effect of central dialysis fluid delivery system on markers of inflammation in hemodialysis patients |
author_sort |
Ni, Yanhong |
journal |
BMC nephrology |
journalStr |
BMC nephrology |
lang_code |
eng |
isOA_bool |
true |
dewey-hundreds |
600 - Technology |
recordtype |
marc |
publishDateSort |
2024 |
contenttype_str_mv |
txt |
author_browse |
Ni, Yanhong Wu, Wenhui Zhou, Hua Li, Min Zhu, Xiying Niu, Hongyan Liu, Jinfeng Xue, Lina Liu, Yeqian Yang, Min |
container_volume |
25 |
class |
610 VZ 44.00 bkl |
format_se |
Elektronische Aufsätze |
author-letter |
Ni, Yanhong |
doi_str_mv |
10.1186/s12882-024-03751-3 |
dewey-full |
610 |
author2-role |
verfasserin |
title_sort |
effect of central dialysis fluid delivery system on markers of inflammation in hemodialysis patients |
title_auth |
Effect of central dialysis fluid delivery system on markers of inflammation in hemodialysis patients |
abstract |
Background The utilization of ultrapure dialysate has been shown to decrease dialysate contamination and mitigate inflammatory responses. The central dialysate delivery system (CDDS) has the potential to attain a level of purity similar to ultrapure dialysate. Nevertheless, there is limited research examining the impact of CDDS on inflammation in comparison to single-patient dialysis fluid delivery system(SPDDS). This study aims to investigate the effects of CDDS utilizing ultrapure dialysate on ameliorating the microinflammatory state in hemodialysis patients. Method A retrospective cohort clinical study enrolled a total of 125 hemodialysis patients, with 58 patients from the CDDS unit and 67 patients from the SPDDS unit. Each participant was monitored for a period of 6 months, and the repeated measurement data was analyzed using a generalized linear mixed models (GLMM). Results The average age of the studty cohort was 56.22 ± 12.64 years. The GLMM analysis showed a significant time*group interaction effect on hs-CRP changes over the follow-up period (β = -1.966, $ F_{Time* CDDS group} $ = 13.389, P < 0.001). A linear mixed model analysis with random slope showed that a different slope was observed between CDDS group and SPDDS group ($ β_{CDDS} $ =—0.793; $ β_{SPDDS} $ = 0.791), indicating a decreased hs-CRP levels in CDDS group, while increased in the SPDDS group over the follow-up period. However, no significant time*group interaction effect were observed on albumin and $ β_{2} $-microglobulin levels during follow-up period($ β_{2} $-microglobulin: β = -0.658, $ F_{Time* CDDS group} $ = 1.228, P = 0.269; albumin: β = 0.012, $ F_{Time* CDDS group} $ = 1.429, P = 0.233). Conclusion Using ultrapure dialysate in the CDDS is associated with an improvement in hs-CRP levels compared to standard dialysate, which might confer long-term clinical advantages. © The Author(s) 2024 |
abstractGer |
Background The utilization of ultrapure dialysate has been shown to decrease dialysate contamination and mitigate inflammatory responses. The central dialysate delivery system (CDDS) has the potential to attain a level of purity similar to ultrapure dialysate. Nevertheless, there is limited research examining the impact of CDDS on inflammation in comparison to single-patient dialysis fluid delivery system(SPDDS). This study aims to investigate the effects of CDDS utilizing ultrapure dialysate on ameliorating the microinflammatory state in hemodialysis patients. Method A retrospective cohort clinical study enrolled a total of 125 hemodialysis patients, with 58 patients from the CDDS unit and 67 patients from the SPDDS unit. Each participant was monitored for a period of 6 months, and the repeated measurement data was analyzed using a generalized linear mixed models (GLMM). Results The average age of the studty cohort was 56.22 ± 12.64 years. The GLMM analysis showed a significant time*group interaction effect on hs-CRP changes over the follow-up period (β = -1.966, $ F_{Time* CDDS group} $ = 13.389, P < 0.001). A linear mixed model analysis with random slope showed that a different slope was observed between CDDS group and SPDDS group ($ β_{CDDS} $ =—0.793; $ β_{SPDDS} $ = 0.791), indicating a decreased hs-CRP levels in CDDS group, while increased in the SPDDS group over the follow-up period. However, no significant time*group interaction effect were observed on albumin and $ β_{2} $-microglobulin levels during follow-up period($ β_{2} $-microglobulin: β = -0.658, $ F_{Time* CDDS group} $ = 1.228, P = 0.269; albumin: β = 0.012, $ F_{Time* CDDS group} $ = 1.429, P = 0.233). Conclusion Using ultrapure dialysate in the CDDS is associated with an improvement in hs-CRP levels compared to standard dialysate, which might confer long-term clinical advantages. © The Author(s) 2024 |
abstract_unstemmed |
Background The utilization of ultrapure dialysate has been shown to decrease dialysate contamination and mitigate inflammatory responses. The central dialysate delivery system (CDDS) has the potential to attain a level of purity similar to ultrapure dialysate. Nevertheless, there is limited research examining the impact of CDDS on inflammation in comparison to single-patient dialysis fluid delivery system(SPDDS). This study aims to investigate the effects of CDDS utilizing ultrapure dialysate on ameliorating the microinflammatory state in hemodialysis patients. Method A retrospective cohort clinical study enrolled a total of 125 hemodialysis patients, with 58 patients from the CDDS unit and 67 patients from the SPDDS unit. Each participant was monitored for a period of 6 months, and the repeated measurement data was analyzed using a generalized linear mixed models (GLMM). Results The average age of the studty cohort was 56.22 ± 12.64 years. The GLMM analysis showed a significant time*group interaction effect on hs-CRP changes over the follow-up period (β = -1.966, $ F_{Time* CDDS group} $ = 13.389, P < 0.001). A linear mixed model analysis with random slope showed that a different slope was observed between CDDS group and SPDDS group ($ β_{CDDS} $ =—0.793; $ β_{SPDDS} $ = 0.791), indicating a decreased hs-CRP levels in CDDS group, while increased in the SPDDS group over the follow-up period. However, no significant time*group interaction effect were observed on albumin and $ β_{2} $-microglobulin levels during follow-up period($ β_{2} $-microglobulin: β = -0.658, $ F_{Time* CDDS group} $ = 1.228, P = 0.269; albumin: β = 0.012, $ F_{Time* CDDS group} $ = 1.429, P = 0.233). Conclusion Using ultrapure dialysate in the CDDS is associated with an improvement in hs-CRP levels compared to standard dialysate, which might confer long-term clinical advantages. © The Author(s) 2024 |
collection_details |
SYSFLAG_0 GBV_SPRINGER SSG-OLC-PHA GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 |
container_issue |
1 |
title_short |
Effect of central dialysis fluid delivery system on markers of inflammation in hemodialysis patients |
url |
https://dx.doi.org/10.1186/s12882-024-03751-3 |
remote_bool |
true |
author2 |
Wu, Wenhui Zhou, Hua Li, Min Zhu, Xiying Niu, Hongyan Liu, Jinfeng Xue, Lina Liu, Yeqian Yang, Min |
author2Str |
Wu, Wenhui Zhou, Hua Li, Min Zhu, Xiying Niu, Hongyan Liu, Jinfeng Xue, Lina Liu, Yeqian Yang, Min |
ppnlink |
326643672 |
mediatype_str_mv |
c |
isOA_txt |
true |
hochschulschrift_bool |
false |
doi_str |
10.1186/s12882-024-03751-3 |
up_date |
2024-09-20T05:14:12.370Z |
_version_ |
1810690738616270848 |
fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000naa a22002652 4500</leader><controlfield tag="001">SPR057390053</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20240920064740.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">240920s2024 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1186/s12882-024-03751-3</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR057390053</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s12882-024-03751-3-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.00</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Ni, Yanhong</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Effect of central dialysis fluid delivery system on markers of inflammation in hemodialysis patients</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2024</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">© The Author(s) 2024</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Background The utilization of ultrapure dialysate has been shown to decrease dialysate contamination and mitigate inflammatory responses. The central dialysate delivery system (CDDS) has the potential to attain a level of purity similar to ultrapure dialysate. Nevertheless, there is limited research examining the impact of CDDS on inflammation in comparison to single-patient dialysis fluid delivery system(SPDDS). This study aims to investigate the effects of CDDS utilizing ultrapure dialysate on ameliorating the microinflammatory state in hemodialysis patients. Method A retrospective cohort clinical study enrolled a total of 125 hemodialysis patients, with 58 patients from the CDDS unit and 67 patients from the SPDDS unit. Each participant was monitored for a period of 6 months, and the repeated measurement data was analyzed using a generalized linear mixed models (GLMM). Results The average age of the studty cohort was 56.22 ± 12.64 years. The GLMM analysis showed a significant time*group interaction effect on hs-CRP changes over the follow-up period (β = -1.966, $ F_{Time* CDDS group} $ = 13.389, P < 0.001). A linear mixed model analysis with random slope showed that a different slope was observed between CDDS group and SPDDS group ($ β_{CDDS} $ =—0.793; $ β_{SPDDS} $ = 0.791), indicating a decreased hs-CRP levels in CDDS group, while increased in the SPDDS group over the follow-up period. However, no significant time*group interaction effect were observed on albumin and $ β_{2} $-microglobulin levels during follow-up period($ β_{2} $-microglobulin: β = -0.658, $ F_{Time* CDDS group} $ = 1.228, P = 0.269; albumin: β = 0.012, $ F_{Time* CDDS group} $ = 1.429, P = 0.233). Conclusion Using ultrapure dialysate in the CDDS is associated with an improvement in hs-CRP levels compared to standard dialysate, which might confer long-term clinical advantages.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Maintenance hemodialysis</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Ultrapure dialysate</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Central Dialysate Delivery system</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">CDDS</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Inflammation</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Wu, Wenhui</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Zhou, Hua</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Li, Min</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Zhu, Xiying</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Niu, Hongyan</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Liu, Jinfeng</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Xue, Lina</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Liu, Yeqian</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Yang, Min</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">BMC nephrology</subfield><subfield code="d">BioMed Central, 2000</subfield><subfield code="g">25(2024), 1 vom: 19. Sept.</subfield><subfield code="w">(DE-627)326643672</subfield><subfield code="w">(DE-600)2041348-8</subfield><subfield code="x">1471-2369</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:25</subfield><subfield code="g">year:2024</subfield><subfield code="g">number:1</subfield><subfield code="g">day:19</subfield><subfield code="g">month:09</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1186/s12882-024-03751-3</subfield><subfield code="m">X:SPRINGER</subfield><subfield code="x">Resolving-System</subfield><subfield code="z">kostenfrei</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_0</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.00</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">25</subfield><subfield code="j">2024</subfield><subfield code="e">1</subfield><subfield code="b">19</subfield><subfield code="c">09</subfield></datafield></record></collection>
|
score |
7.3986425 |